Quantitative Flow Ratio (QFR) Guided Coronary Artery Bypass Grafting for Patients Undergoing Primary Valve Surgery With Concomitant Coronary Artery Disease

NAActive, not recruitingINTERVENTIONAL
Enrollment

792

Participants

Timeline

Start Date

August 4, 2019

Primary Completion Date

September 30, 2024

Study Completion Date

August 31, 2027

Conditions
Primary Valvular Heart Disease With Comorbid Coronary Artery DiseasePlanned to Undergo Elective On-pump Valve Surgery Due to Primary Mitral and/or Aortic Valvular Heart Disease
Interventions
DEVICE

QFR-guided strategy

In this study, the QFR-guided strategy will be applied to in the QFR group in which calculation of the QFR values of all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and with suitability to CABG revascularization will be carried out. If QFR ≤ 0.80, then simultaneous CABG revascularization of target blood vessels will be carried out. If QFR \> 0.80, then no CABG revascularization of target blood vessels will be carried out.

OTHER

CAG-guided strategy

In this study, CAG-guided strategy will be used for the control group, i.e., in accordance with current guideline recommendations, all target coronary arteries with lesions with diameter stenosis of ≥ 50% (visual estimation) and suited for CABG revascularization will undergo CABG revascularization.

Trial Locations (12)

200025

Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

Unknown

The First Affiliated Hospital of Anhui Medical University, Hefei

Fujian Medical University Union Hospital, Fuzhou

Fuwai Central China Cardiovascular Hospital, Zhengzhou

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

The Second XiangYa Hospital of Central South University, Changsha

Qilu Hospital of Shandong University, Jinan

The Affiliated Hospital of Qingdao University, Qingdao

Changhai Hospital of Shanghai, Shanghai

Shanghai Chest Hospital, Shanghai

Tianjin Chest Hospital, Tianjin

The First Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

Med-X Research Institute, Shanghai Jiao Tong University

UNKNOWN

lead

Ruijin Hospital

OTHER